Anti-inflammatory peptides and use thereof
Isolated peptides of 13-30 amino acids comprising 5-9 consecutive repeats of the amino acid pair Alanine-Leucine or Alanine-Valine are provided. The peptides further comprise a stretch of 1-3 Lysine residues present at least at one of the peptide's termini, wherein the only Lysine residue in the isolated peptide is present at the stretch of 1-3 Lysine residues. Pharmaceutical compositions comprising same, methods of treating inflammatory conditions and allergic reactions, as well as methods of neutralizing the activity of lypopolysaccharides are also provided.
1. An isolated peptide of 13-30 amino acids comprising the formula of K n (AX 1 ) m X 2 K n , wherein X 1 is Leucine (L), X 2 is absent or Alanine, n, at each occurrence is independently 0-3 with the proviso that at least one terminal Lysine (K) is present, and m is 5-9.
2. The isolated peptide of claim 1 , wherein a stretch of 1-3 Lysine residues is present at said peptide's N-terminus and C-terminus.
3. The isolated peptide of claim 1 , comprising the formula of K n (AL) m K n , wherein n, at each occurrence is independently 0-2 with the proviso that at least one terminal Lysine (K) is present, and m is 6-9.
4. The isolated peptide of claim 3 selected from the group consisting of: (SEQ ID NO: 1) KK(AL) 8 KK; (SEQ ID NO: 2) (AL) 9 KK; (SEQ ID NO: 3) K(AL) 9 K; and (SEQ ID NO: 4) (AL) 7 K.
5. The isolated peptide of claim 3 , as set forth in SEQ ID NO: 1.
6. The isolated peptide of claim 1 , comprising the formula of K n (AL) m K n , wherein n, at each occurrence is independently 0-2 with the proviso that at least one terminal Lysine (K) is present, and m is 5-9.
7. The isolated peptide of claim 1 selected from the group consisting of: (SEQ ID NO: 5) KK(AL) 5 AKK; (SEQ ID NO: 6) (AL) 6 AKK; and (SEQ ID NO: 7) K(AL) 6 AK.
8. The isolated peptide according to claim 1 , wherein the peptide comprises at least one D amino acid.
9. A pharmaceutical composition comprising as an active ingredient an isolated peptide according to claim 1 , and a pharmaceutically acceptable carrier.
10. A method of treating an inflammatory condition in a subject in need thereof comprising administering to the subject a therapeutically acceptable amount of the pharmaceutical composition of claim 9 , wherein the inflammatory condition is selected from the group consisting of microbial infection, systemic inflammatory response syndrome (SIRS), sepsis, septicemia, septic shock, a mast cell-related disease, and an allergic reaction.
11. The method of claim 10 , wherein the allergic reaction is an IgE-mediated allergic disorder.
12. The method of claim 11 , wherein the IgE-mediated allergic disorder is selected from the group consisting of: allergy-induced asthma, hypersensitivity, eczema conjunctivitis, urticaria, rhinorrhea, rhinitis gastroenteritis, food allergies, pemphigus vulgaris, atopic dermatitis, eosinophilia and allergic bronchopulmonary aspergillosis.
13. A method of neutralizing the activity of lipopolysaccharides (LPS) endotoxin in a subject in need thereof comprising administering to the subject a pharmaceutically acceptable amount of the pharmaceutical composition of claim 9 .
14. The method of claim 13 , for preventing, neutralizing or reducing endotoxemia or endotoxin-induced septic shock.